Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Reporting recommendations for tumor marker prognostic studies (REMARK).

Lisa M McShane1, Douglas G Altman, Willi Sauerbrei

  • 1Biometric Research Branch, National Cancer Institute, Executive Plaza North, 6130 Executive Blvd., Bethesda, MD 20892-7434, USA. lm5h@nih.gov

Journal of the National Cancer Institute
|August 18, 2005
PubMed
Summary

Clinical utility of cancer tumor markers is limited due to inconsistent study results. Developing clear reporting guidelines is crucial for evaluating marker reliability and clinical usefulness in oncology.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population attributable fraction.

BMJ (Clinical research ed.)·2018
Same author

Reporting guidelines for oncology research: helping to maximise the impact of your research.

British journal of cancer·2018
Same author

Updating standards for reporting diagnostic accuracy: the development of STARD 2015.

Research integrity and peer review·2018
Same author

Do declarative titles affect readers' perceptions of research findings? A randomized trial.

Research integrity and peer review·2018
Same author

Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries.

PloS one·2018
Same author

The INTERGROWTH-21<sup>st</sup> fetal growth standards: toward the global integration of pregnancy and pediatric care.

American journal of obstetrics and gynecology·2018

Area of Science:

  • Oncology
  • Biomarker Research
  • Clinical Diagnostics

Background:

  • Numerous tumor markers show initial promise but yield inconsistent results in subsequent studies.
  • Discrepancies in tumor marker research hinder the identification of clinically useful diagnostic tools.
  • Lack of rigorous reporting in many studies prevents adequate assessment of quality and generalizability.

Framework:

  • Proposes guidelines for reporting tumor marker studies, inspired by CONSORT and STARD initiatives.
  • Addresses the need for standardized reporting to improve study quality and reproducibility.

Implementation:

  • Guidelines cover study design, hypotheses, patient/specimen details, assay methods, and statistical analysis.
  • Emphasizes transparent and complete reporting of all study aspects.

Related Experiment Videos

Implications:

  • Aims to enable better judgment of tumor marker data usefulness and generalizability.
  • Enhances the reliability and interpretability of cancer diagnostics research.